These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16669956)

  • 1. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
    van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
    Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB; Wedel MK; Xia S; Baker BF
    Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
    Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
    Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
    Miner P; Wedel M; Bane B; Bradley J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
    Vegter S; Tolley K; Wilson Waterworth T; Jones H; Jones S; Jewell D
    Aliment Pharmacol Ther; 2013 Aug; 38(3):284-93. PubMed ID: 23750909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
    Greuter T; Vavricka SR; Biedermann L; Pilz J; Borovicka J; Seibold F; Sauter B; Rogler G
    Dig Dis; 2018; 36(2):123-129. PubMed ID: 29207381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT; Sitaraman SV
    Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
    Schreiber S; Keshavarzian A; Isaacs KL; Schollenberger J; Guzman JP; Orlandi C; Hanauer SB
    Gastroenterology; 2007 Jan; 132(1):76-86. PubMed ID: 17241861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.